(Q83340709)

English

A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study

scientific article published on 01 November 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699973%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699973%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

phase II clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

James Lewis Abbruzzese

10

object named as

James L Abbruzzese

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699973%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

Robert P Whitehead

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699973%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Sheryl McCoy

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699973%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Saul E Rivkin

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699973%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Howard M Gross

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699973%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Marcel E Conrad

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699973%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Gary C Doolittle

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699973%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Robert A Wolff

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699973%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

J Wendall Goodwin

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699973%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Shaker R Dakhil

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699973%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

publication date

1 November 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699973%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699973%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699973%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699973%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

515-520

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699973%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

https://scigraph.springernature.com/pub.10.1007/s10637-006-8440-x

0 references

Phase II study of gemcitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-006-8440-X

21 January 2018

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1 reference

https://pubmed.ncbi.nlm.nih.gov/16699973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16699973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

https://pubmed.ncbi.nlm.nih.gov/16699973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2004

1 reference

https://pubmed.ncbi.nlm.nih.gov/16699973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16699973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16699973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/16699973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16699973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/16699973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16699973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16699973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83340709&oldid=1818656857"